 |
PDBsum entry 1p4f
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
Death associated protein kinase catalytic domain with bound inhibitor fragment
|
|
Structure:
|
 |
Death-associated protein kinase 1. Chain: a. Fragment: catalytic domain, protein kinase domain. Synonym: dap kinase 1. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: dapk1 or dapk. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
1.90Å
|
R-factor:
|
0.186
|
R-free:
|
0.233
|
|
|
Authors:
|
 |
A.V.Velentza,M.S.Wainwright,M.Zasadzki,S.Mirzoeva,J.Haiech,P.J.Focia, M.Egli,D.M.Watterson
|
|
Key ref:
|
 |
A.V.Velentza
et al.
(2003).
An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury.
Bioorg Med Chem Lett,
13,
3465-3470.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
23-Apr-03
|
Release date:
|
28-Sep-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P53355
(DAPK1_HUMAN) -
Death-associated protein kinase 1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
1430 a.a.
269 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 2 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.11.1
- non-specific serine/threonine protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Bioorg Med Chem Lett
13:3465-3470
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury.
|
|
A.V.Velentza,
M.S.Wainwright,
M.Zasadzki,
S.Mirzoeva,
A.M.Schumacher,
J.Haiech,
P.J.Focia,
M.Egli,
D.M.Watterson.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Death associated protein kinase (DAPK) is a calcium and calmodulin regulated
enzyme that functions early in eukaryotic programmed cell death, or apoptosis.
To validate DAPK as a potential drug discovery target for acute brain injury,
the first small molecule DAPK inhibitor was synthesized and tested in vivo. A
single injection of the aminopyridazine-based inhibitor administered 6 h after
injury attenuated brain tissue or neuronal biomarker loss measured,
respectively, 1 week and 3 days later. Because aminopyridazine is a privileged
structure in neuropharmacology, we determined the high-resolution crystal
structure of a binary complex between the kinase domain and a molecular fragment
of the DAPK inhibitor. The co-crystal structure describes a structural basis for
interaction and provides a firm foundation for structure-assisted design of lead
compounds with appropriate molecular properties for future drug development.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
L.K.McNamara,
J.S.Brunzelle,
J.P.Schavocky,
D.M.Watterson,
and
V.Grum-Tokars
(2011).
Site-directed mutagenesis of the glycine-rich loop of death associated protein kinase (DAPK) identifies it as a key structure for catalytic activity.
|
| |
Biochim Biophys Acta,
1813,
1068-1073.
|
 |
|
|
|
|
 |
B.N.Kang,
A.S.Ahmad,
S.Saleem,
R.L.Patterson,
L.Hester,
S.Doré,
and
S.H.Snyder
(2010).
Death-associated protein kinase-mediated cell death modulated by interaction with DANGER.
|
| |
J Neurosci,
30,
93-98.
|
 |
|
|
|
|
 |
E.Y.Cho,
S.J.Lee,
K.W.Nam,
J.Shin,
K.B.Oh,
K.H.Kim,
and
W.Mar
(2010).
Amelioration of oxygen and glucose deprivation-induced neuronal death by chloroform fraction of bay leaves (Laurus nobilis).
|
| |
Biosci Biotechnol Biochem,
74,
2029-2035.
|
 |
|
|
|
|
 |
M.Zimmermann,
C.Atmanene,
Q.Xu,
L.Fouillen,
A.Van Dorsselaer,
D.Bonnet,
C.Marsol,
M.Hibert,
S.Sanglier-Cianferani,
C.Pigault,
L.K.McNamara,
D.M.Watterson,
J.Haiech,
and
M.C.Kilhoffer
(2010).
Homodimerization of the death-associated protein kinase catalytic domain: development of a new small molecule fluorescent reporter.
|
| |
PLoS One,
5,
e14120.
|
 |
|
|
|
|
 |
N.Gavande,
G.A.Johnston,
J.R.Hanrahan,
and
M.Chebib
(2010).
Microwave-enhanced synthesis of 2,3,6-trisubstituted pyridazines: application to four-step synthesis of gabazine (SR-95531).
|
| |
Org Biomol Chem,
8,
4131-4136.
|
 |
|
|
|
|
 |
L.K.Chico,
L.J.Van Eldik,
and
D.M.Watterson
(2009).
Targeting protein kinases in central nervous system disorders.
|
| |
Nat Rev Drug Discov,
8,
892-909.
|
 |
|
|
|
|
 |
L.K.McNamara,
D.M.Watterson,
and
J.S.Brunzelle
(2009).
Structural insight into nucleotide recognition by human death-associated protein kinase.
|
| |
Acta Crystallogr D Biol Crystallogr,
65,
241-248.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Stevens,
Y.Lin,
M.Sanchez,
E.Amin,
E.Copson,
H.White,
V.Durston,
D.M.Eccles,
and
T.Hupp
(2007).
A germ line mutation in the death domain of DAPK-1 inactivates ERK-induced apoptosis.
|
| |
J Biol Chem,
282,
13791-13803.
|
 |
|
|
|
|
 |
E.Ihara,
and
J.A.MacDonald
(2007).
The regulation of smooth muscle contractility by zipper-interacting protein kinase.
|
| |
Can J Physiol Pharmacol,
85,
79-87.
|
 |
|
|
|
|
 |
L.Munoz,
H.R.Ranaivo,
S.M.Roy,
W.Hu,
J.M.Craft,
L.K.McNamara,
L.W.Chico,
L.J.Van Eldik,
and
D.M.Watterson
(2007).
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
|
| |
J Neuroinflammation,
4,
21.
|
 |
|
|
|
|
 |
Y.Li,
and
A.Grupe
(2007).
Genetics of late-onset Alzheimer's disease: progress and prospect.
|
| |
Pharmacogenomics,
8,
1747-1755.
|
 |
|
|
|
|
 |
M.Schmitt,
J.X.de Araújo-Júnior,
S.Oumouch,
and
J.J.Bourguignon
(2006).
Use of 4-bromo pyridazine 3,6-dione for building 3-amino pyridazine libraries.
|
| |
Mol Divers,
10,
429-434.
|
 |
|
|
|
|
 |
M.Shamloo,
L.Soriano,
T.Wieloch,
K.Nikolich,
R.Urfer,
and
D.Oksenberg
(2005).
Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia.
|
| |
J Biol Chem,
280,
42290-42299.
|
 |
|
|
|
|
 |
R.Schneider-Stock,
A.Roessner,
and
O.Ullrich
(2005).
DAP-kinase--protector or enemy in apoptotic cell death.
|
| |
Int J Biochem Cell Biol,
37,
1763-1767.
|
 |
|
|
|
|
 |
J.M.Craft,
D.M.Watterson,
S.A.Frautschy,
and
L.J.Van Eldik
(2004).
Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo.
|
| |
Neurobiol Aging,
25,
1283-1292.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |